Wenmin Chen

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Drug Administration

Radiation Therapy

Top Venues

Integrative cancer therapies

This page only lists publications with an associated author ORCID identifier.

Publications

Wenmin Chen, Jietao Lin, Ting Yang, Ze Xin Zhang, Lanting Tao, Zhiwei Xiao, Hanrui Chen, Xiangjun Qi, Lingling Sun, Yang Cao, Li-Zhu Lin
Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study. Integrative cancer therapies 22 (2023)
Wenmin Chen, Jietao Lin, Ting Yang, Ze Xin Zhang, Lanting Tao, Zhiwei Xiao, Hanrui Chen, Xiangjun Qi, Lingling Sun, Yang Cao, Li-Zhu Lin
Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study. Integrative cancer therapies 22 (2023)
Jietao Lin, Lingling Sun, Hanrui Chen, Wenmin Chen, Zexin Zhang, Yang Cao, Li-Zhu Lin
Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort). Integrative cancer therapies 22 (2023)
Wenmin Chen, Jietao Lin, Ting Yang, Ze Xin Zhang, Lanting Tao, Zhiwei Xiao, Hanrui Chen, Xiangjun Qi, Lingling Sun, Yang Cao, Li-Zhu Lin
Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study. Integrative cancer therapies 22 (2023)